Vyne Therapeutics Inc (VYNE)

Mar 21, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN

Mar 21, 2025

Mar 20, 2025

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 20, 2025

Mar 20, 2025

VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan

Mar 20, 2025

Mar 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 08, 2025

Mar 07, 2025

VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks

Mar 07, 2025

Mar 07, 2025

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 07, 2025

Mar 06, 2025

VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com

Mar 06, 2025

Mar 06, 2025

VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz

Mar 06, 2025

Mar 06, 2025

VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Mar 06, 2025

Mar 06, 2025

Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

Mar 06, 2025

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times

Mar 06, 2025

Mar 06, 2025

Can VYNE's $61.5M War Chest Drive Success in Vitiligo and Psoriasis Trials? - Stock Titan

Mar 06, 2025

Feb 27, 2025

VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Feb 21, 2025

HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Feb 21, 2025

Feb 20, 2025

VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times

Feb 20, 2025

Feb 20, 2025

Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan

Feb 20, 2025

Feb 19, 2025

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq

Feb 19, 2025

Feb 19, 2025

Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times

Feb 19, 2025

Feb 19, 2025

Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan

Feb 19, 2025

Jan 20, 2025

VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World

Jan 20, 2025

Jan 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia

Jan 17, 2025

Jan 17, 2025

Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus

Jan 17, 2025

Jan 14, 2025

VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat

Jan 14, 2025

Jan 13, 2025

Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail

Jan 13, 2025

Jan 10, 2025

Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Jan 10, 2025

Jan 07, 2025

VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance

Jan 07, 2025

Jan 07, 2025

VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jan 07, 2025

Jan 06, 2025

Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga

Jan 06, 2025

Jan 06, 2025

VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 06, 2025

Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com

Jan 06, 2025

Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ

Jan 06, 2025

Jan 06, 2025

VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan

Jan 06, 2025

Jan 02, 2025

VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa

Jan 02, 2025

Jan 02, 2025

VYNE stock soars to 52-week high, touches $3.43 - Investing.com

Jan 02, 2025

Dec 26, 2024

VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World

Dec 26, 2024

Dec 24, 2024

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance

Dec 24, 2024

Dec 24, 2024

VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Dec 24, 2024

Dec 23, 2024

VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times

Dec 23, 2024

Dec 23, 2024

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times

Dec 23, 2024

Dec 15, 2024

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 37.1% - Defense World

Dec 15, 2024

Dec 12, 2024

VYNE Therapeutics Sees Strong Shareholder Support for Growth - TipRanks

Dec 12, 2024

Nov 29, 2024

Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail

Nov 29, 2024

Nov 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 24, 2024